In early March I joined a phase-2 trial (study) of Celgene's new IMiD drug CC-4047, with once-weekly dexamethasone. The first three one-month cycles brought very good results, each with approximately a 25% reduction in markers, but the fourth and fifth cycles have been less spectacular. My two primary markers are IgG and M-spike: So the bad news is that there is no change, at least none for sure. The good news is that there is no indication at all that the tumor burden is climbing again, as it had at every test for the previous five years. More important, IgG is in a "normal" range and M-Spike is at a value last seen three years ago. I hope for more improvement, but if none comes I'm still far better off than before I started on the drug trial. Life is great!

We will continue with 2 mg of CC-4047 daily and 20 mg DEX once weekly for the sixth cycle. Here are some related links:

      My Myeloma     A discussion of my myeloma, not very technical.
My Treatment History Not technical.
My Test Charts Graphic displays of several key test results over time.
My Test Result Table Best with a wide browser window. Very "technical."

Side effects of the two drugs, CC-4047 and dexamethasone (DEX), are described in a previous post.

Other things that came up: Here are a few specific test results:

Test   May 29     Jun 26     Jul 24     Remarks
IgG mg/dL 1260 1450 1330 Some variation is normal
M-spike g/dL 1.2 1.1 1.1 Best tumor measure
L FLC mg/dL 4.25 4.03 3.30 Down is good
Calcium mg/dL 9.7 10.1 9.7 Below 1.2 is best
Creat mg/dL 1.1 1.0 1.0 Liver function, low is better